Literature DB >> 18500380

The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

E Davis1, R Loiacono, R J Summers.   

Abstract

Athletes attempt to improve performance with drugs that act on the beta-adrenergic system directly or indirectly. Of three beta-adrenoceptor (AR) subtypes, the beta(2)-AR is the main target in sport; they have bronchodilator and anabolic actions and enhance anti-inflammatory actions of corticosteroids. Although demonstrable in animal experiments and humans, there is little evidence that these properties can significantly improve performance in trained athletes. Their actions may also be compromised by receptor desensitization and by common, naturally occurring receptor mutations (polymorphisms) that can influence receptor signalling and desensitization properties in individuals. Indirectly acting agents affect release and reuptake of noradrenaline and adrenaline, thereby influencing all AR subtypes including the three beta-ARs. These agents can have potent psychostimulant effects that provide an illusion of better performance that does not usually translate into improvement in practice. Amphetamines and cocaine also have considerable potential for cardiac damage. beta-AR antagonists (beta-blockers) are used in sports that require steadiness and accuracy, such as archery and shooting, where their ability to reduce heart rate and muscle tremor may improve performance. They have a deleterious effect in endurance sports because they reduce physical performance and maximum exercise load. Recent studies have identified that many beta-AR antagonists not only block the actions of agonists but also activate other (mitogen-activated PK) signalling pathways influencing cell growth and fate. The concept that many compounds previously regarded as 'blockers' may express their own spectrum of pharmacological properties has potentially far-reaching consequences for the use of drugs both therapeutically and illicitly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500380      PMCID: PMC2439523          DOI: 10.1038/bjp.2008.164

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  151 in total

Review 1.  The efficacy of ergogenic agents in athletic competition. Part II: Other performance-enhancing agents.

Authors:  D A Smith; P J Perry
Journal:  Ann Pharmacother       Date:  1992-05       Impact factor: 3.154

Review 2.  Is the adipocyte beta-adrenoceptor a prototype for the recently cloned atypical 'beta 3-adrenoceptor'?

Authors:  J Zaagsma; S R Nahorski
Journal:  Trends Pharmacol Sci       Date:  1990-01       Impact factor: 14.819

Review 3.  Is there a third heart beta-adrenoceptor?

Authors:  A J Kaumann
Journal:  Trends Pharmacol Sci       Date:  1989-08       Impact factor: 14.819

Review 4.  Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue.

Authors:  Y T Yang; M A McElligott
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

5.  Fenoterol and asthma mortality.

Authors:  N Pearce; J Crane; C Burgess; R Beasley; R Jackson
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

6.  Molecular characterization of the human beta 3-adrenergic receptor.

Authors:  L J Emorine; S Marullo; M M Briend-Sutren; G Patey; K Tate; C Delavier-Klutchko; A D Strosberg
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

7.  Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor.

Authors:  D P McLaughlin; A MacDonald
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  Expression of beta 3-adrenoceptor mRNA in rat brain.

Authors:  R J Summers; M Papaioannou; S Harris; B A Evans
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles.

Authors:  Y S Kim; R D Sainz; R J Summers; P Molenaar
Journal:  J Anim Sci       Date:  1992-01       Impact factor: 3.159

10.  Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein.

Authors:  P Molenaar; E Malta; C R Jones; B F Buxton; R J Summers
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

View more
  9 in total

Review 1.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

2.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

3.  Attitudes and motivations of competitive cyclists regarding use of banned and legal performance enhancers.

Authors:  Nkaku R Kisaalita; Michael E Robinson
Journal:  J Sports Sci Med       Date:  2014-01-20       Impact factor: 2.988

4.  [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].

Authors:  S J Liu; H M Hou; Z T Lv; X Ding; L Wang; L Zhang; M Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

5.  [Anesthesia management of athletes' operation in Beijing Olympic Winter Games].

Authors:  Z Y Kang; L L Wang; Y Z Han; X Y Guo
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

6.  Drugs in sport.

Authors:  J C McGrath; D A Cowan
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

7.  Agonist-directed desensitization of the β2-adrenergic receptor.

Authors:  Vasiliy Goral; Yan Jin; Haiyan Sun; Ann M Ferrie; Qi Wu; Ye Fang
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

Review 8.  Genetic factors associated with exercise performance in atmospheric hypoxia.

Authors:  Philip J Hennis; Alasdair F O'Doherty; Denny Z H Levett; Michael P W Grocott; Hugh M Montgomery
Journal:  Sports Med       Date:  2015-05       Impact factor: 11.136

Review 9.  Drug abuse in athletes.

Authors:  Claudia L Reardon; Shane Creado
Journal:  Subst Abuse Rehabil       Date:  2014-08-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.